Centro De Inmunologia Molecular

Audry Fernández Gómez

Luis Enrique Fernández Molina

Circe Mesa Pardillo

Belinda Sánchez Ramírez

Jesús Arturo Junco Barranco

Mabel Cruz Rodríguez

Irene Beausoleil Delgado

Diana Rosa Hernández Fernández

Narjara González Suárez

Lisset Chao García

Gretchen Bergado Báez

Ángel Alexis Manso Vargas

Blanca Idelmis Tolón Murguía

Miguel Antonio López López

Vicente Guillermo Verez Bencomo

Dayana Pérez Martínez

Maura Lisett Rábade Chediak

Idelmis Curbelo Haredia

Liliana Oliver Ríos

Orlando Valdés Guerrero

Lena Aguiar García

Rydell Alvarez Arzola

Elias Antonio Gracia Medina

Lourdes Hernández De La Rosa

Vladimir Peña Sánchez

Leslie Pérez Ruíz

Anet Valdés Zayas

María Caridad Rubio Hernández

Camilo Rodríguez Rodríguez

Rolando Pérez Rodríguez

Greta Garrido Hidalgo

Alejandro López Requena

This invention describes ways of obtaining nano-particulated adjuvants formed by different synthetic variants of GM3 ganglioside. Depending on the fine structure of the fatty acid in the ceramide of the synthetic GM3, said adjuvants are able to stimulate specifically and in a specialized way the humoral or cellular immune response against accompanying antigens. Particularly, this invention provides immunogenic vaccine compositions that comprise peptides, polypeptides or proteins and the aforementioned nanoparticles, which are formed through the dispersion of hydrophobic proteins of the outer membrane complex (OMC) ofin solutions containing fully synthetic variants of the GM3 ganglioside.

Nano-particles that contain synthetic variants of GM3 ganglioside as adjuvants in vaccines

The present invention describes a pharmaceutical composition whose active ingredient includes conjugates of membrane vesicles ofand the GM3 ganglioside in a conjugation ratio in excess of proteins, has particular characteristics of size, surface charge and a morphology associated with nano-particulate systems that give it advantageous properties as an immunomodulator, because it induces a convenient and significant reduction of myeloid-derived suppressor cells that has an impact on the response of lymphocytes and on the survival of patients with tumors. The invention further discloses the use of the pharmaceutical composition disclosed in the treatment of cancer, particularly those cancers where the myeloid-derived suppressor cells (MDSCs) are high; as well as a method of treatment with said composition in cancer patients and a method to select those who will receive said treatment.

Ganglioside GM3-containing nanoparticles as immunomodulators

Growing community of inventors

Havana, Cuba

Audry Fernández Gómez